Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
7MW3711 in Advanced Solid Tumors
NCT06008366Phase 2Recruiting
- Sponsor
- Mabwell
- Start
- Sep 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of 7MW3711 in solid tumor, sponsored by Mabwell. Started Sep 2023; status: recruiting.
02
Drugs
7MW3711
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06008366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06008366.